Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Deenik
W
W
Beverloo
H B
HB
van der Poel-van de Luytgaarde
S C P A M
SC
Wattel
M M
MM
van Esser
J W J
JW
Valk
P J M
PJ
Cornelissen
J J
JJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D000069439:Dasatinib; D003630:Daunorubicin / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D009363:Neoplasm Proteins / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics; D036102:Peripheral Blood Stem Cell Transplantation; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000601:surgery; D011241:Prednisone / Q000008:administration & dosage; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D013161:Splenic Rupture / Q000209:etiology / Q000601:surgery; D013844:Thiazoles / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
C521114:NUP214-ABL1 fusion protein, human; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D011743:Pyrimidines; D013844:Thiazoles; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D008942:Mitoxantrone; D001215:Asparaginase; D000069439:Dasatinib; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin